

Haematologica
HAEMATOL/2020/249649
Version 3

Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and
ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase
inhibition

JinJuan Yao, Lianrong Xu, Umut Aypar, Howard J. Meyerson, Dory Londono, Qi Gao, Jeeyeon Baik, James Dietz, Ryma Benayed, Allison Sigler, Mariko Yabe, Ahmet Dogan, Maria E. Arcila, Mikhail Roshal, Yanming Zhang, Michael J. Mauro, and Wenbin Xiao

Disclosures: W.X. has received research support from Stemline Therapeutics. M.J. M. has served as a consultant/advisor for Novartis, Pfizer, Bristol-Myers Squibb, Takeda/Millennium, and receives institutional research support from Bristol-Myers Squibb, Novartis, and Sun Pharma/SPARC. The other authors have nothing to disclose.

Contributions: Contributions: J.Y., L.X., Y.Z., M.J.M., and W.X. conceived the study, collected and analyzed the data, and wrote the manuscript. U.A., D.L., and Y.Z. performed cytogenetic studies and interpreted the data. H.M. contributed critical clinical materials. Q.G., J.B., J.D., R.B., M.Y., N.S., and A.E.M. collected data. A.D. and M.R. interpreted the data. All the authors approved the final version of the manuscript.